LIGAND PHARMACEUTICALS INC — Director's Dealing 2021

Feb 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2021-02-15

Reporting Person: Korenberg Matthew E (EVP,Finance & Strategy and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-15	Common Stock	F	434	$172.46	Disposed	41318	Direct
2021-02-15	Common Stock	F	906	$172.46	Disposed	40412	Direct
2021-02-15	Common Stock	F	969	$172.46	Disposed	39443	Direct

Footnotes

F1: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 03/02/2018.

F2: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019.

F3: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020.